GHRL and metabolic syndrome: Administration of ghrelin in persons with metabolic syndrome is shown to improve endothelial function by preventing proatherogenic changes [100] and improving vasodilatation [101], by decreasing blood pressure (BP) without an increase in heart rate [102], and additional haemodynamic effects by increasing cardiac output [103].